Although I am already heavily overweight TRS, I bought another...

Although I am already heavily overweight TRS, I bought another decent parcel today. While we are all in the dark until the next announcement, the facts as I see them make the current price too good to pass up. If we assume the company will hit guidance this year, there should be a minimum $2m upside next year from the benefits of the HK office, DC ramp up, and an improved Q1. Things can always go awry, but I can't see patient holders being disappointed at the current share price if they are prepared to ride out the volatility.